Predictive Oncology Files 8-K

TL;DR

Predictive Oncology filed an 8-K, but no major news yet.

AI Summary

Predictive Oncology Inc. filed an 8-K on October 29, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Skyline Medical Inc., is incorporated in Delaware and headquartered in Pittsburgh, PA. This filing does not contain specific financial details or material events beyond the reporting of these categories.

Why It Matters

This 8-K filing indicates that Predictive Oncology Inc. has submitted required documentation to the SEC, but it does not disclose specific material events or financial performance.

Risk Assessment

Risk Level: low — The filing is a routine procedural update and does not contain information that would immediately impact the company's risk profile.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• Skyline Medical Inc. (company) — Former company name
• October 29, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Pittsburgh, Pennsylvania (location) — Business address

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share POAI NASDAQ Capital Market
• $18,330,000 — ng an aggregate offering price of up to $18,330,000. However, in the event that the Company
• $75.0 m — Company's public float increases above $75.0 million, it will no longer be subject to
• $2,417,337 — aggregate market value of approximately $2,417,337 pursuant to General Instruction I.B.6 o

Filing Documents

• f8k_102925.htm (8-K) — 25KB
• exh_51.htm (EX-5.1) — 22KB
• dlapiper.jpg (GRAPHIC) — 4KB
• 0001171843-25-006772.txt ( ) — 221KB
• poai-20251029.xsd (EX-101.SCH) — 3KB
• poai-20251029_lab.xml (EX-101.LAB) — 33KB
• poai-20251029_pre.xml (EX-101.PRE) — 22KB
• f8k_102925_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On October 29, 2025, Predictive Oncology Inc., a Delaware corporation, (the "Company"), filed a prospectus supplement (the "Prospectus Supplement) to the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of its registration statement on Form S-3 (333-279123) (the "Registration Statement"), as supplemented by its prospectus supplement, dated May 21, 2024, as further supplemented by the prospectus supplements dated April 18, 2025 and June 2, 2025 (collectively, the "ATM Prospectus"). The Company previously entered into an ATM Sales Agreement (the "Agreement") on May 3, 2024 with H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent, to sell shares of the Company's common stock, par value $0.01 per share, from time to time, through an "at the market offering" program pursuant to which Wainwright will act as sales agent. The Company filed the Prospectus Supplement to amend the ATM Prospectus to update the maximum amount of shares that it is eligible to sell from and after October 29, 2025, and to specify the value of common stock it would be permitted to sell in any 12-calendar month period under General Instruction I.B.6 of Form S-3. As of October 29, 2025, the Company could only offer and sell shares of its common stock having an aggregate offering price of up to $18,330,000. However, in the event that the Company's public float increases or decreases, it may sell securities in public primary offerings on Form S-3 with a value up to one-third of the Company's public float, in each case calculated pursuant to General Instruction I.B.6 of Form S-3 and subject to the terms of the Agreement. In the event that the Company's public float increases above $75.0 million, it will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If the Company's public float increases such that it may sell additional amounts under the Agreement and the Form S-3 registration statement of which the

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 5.1 Opinion of DLA Piper LLP 23.1 Consent of DLA Piper LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY INC. Date: October 29, 2025 By: /s/ Josh Blacher Josh Blacher Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR